ATROVENT HFA METERED-DOSE AEROSOL

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

IPRATROPIUM BROMIDE

থেকে পাওয়া:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

এটিসি কোড:

R03BB01

INN (আন্তর্জাতিক নাম):

IPRATROPIUM BROMIDE

ডোজ:

20MCG

ফার্মাসিউটিকাল ফর্ম:

METERED-DOSE AEROSOL

রচনা:

IPRATROPIUM BROMIDE 20MCG

প্রশাসন রুট:

INHALATION

প্যাকেজ ইউনিট:

200 METERED DOSES

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANTIMUSCARINICS ANTISPASMODICS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0115643002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2003-07-02

পণ্য বৈশিষ্ট্য

_ _
Atrovent HFA Product Monograph November 4, 2019
Page 1 of 30
PRODUCT MONOGRAPH
PR
ATROVENT
® HFA
(IPRATROPIUM BROMIDE)
PRESSURIZED INHALATION SOLUTION
20 MCG/METERED DOSE
BRONCHODILATOR
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road,
Burlington, Ontario
L7L 5H4
Date of Revision:
November 4, 2019
Submission Control No: 230291
BICL-CCDS No. 0260-02
_ _
Atrovent HFA Product Monograph November 4, 2019
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................15
SPECIAL HANDLING INSTRUCTIONS
.......................................................................15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL INFORMATION
.............................................